Tonix Pharmaceuticals (NASDAQ:TNXP) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Tonix Pharmaceuticals (NASDAQ:TNXP) from a hold rating to a sell rating in a research report sent to investors on Friday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Saturday, September 27th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tonix Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $70.00.

Tonix Pharmaceuticals Price Performance

Shares of Tonix Pharmaceuticals stock opened at $24.00 on Friday. The firm has a fifty day moving average price of $34.42 and a 200 day moving average price of $30.80. Tonix Pharmaceuticals has a 1 year low of $6.76 and a 1 year high of $130.00. The stock has a market cap of $210.48 million, a PE ratio of -0.61 and a beta of 1.87.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Monday, August 11th. The company reported ($3.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.10) by ($0.76). Tonix Pharmaceuticals had a negative return on equity of 57.93% and a negative net margin of 828.22%.The business had revenue of $2.00 million for the quarter, compared to analysts’ expectations of $2.60 million. As a group, equities analysts expect that Tonix Pharmaceuticals will post -1762.5 EPS for the current year.

Institutional Trading of Tonix Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC grew its position in shares of Tonix Pharmaceuticals by 108.4% in the second quarter. Tower Research Capital LLC TRC now owns 7,172 shares of the company’s stock valued at $258,000 after purchasing an additional 3,731 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Tonix Pharmaceuticals in the second quarter valued at about $65,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Tonix Pharmaceuticals in the second quarter valued at about $149,000. JT Stratford LLC acquired a new stake in shares of Tonix Pharmaceuticals in the second quarter valued at about $232,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Tonix Pharmaceuticals in the second quarter valued at about $104,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.